Background/Aims: MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner. Downregulated microRNAs and their roles in cancer development have attracted much attention. A growing body of evidence showed that microRNA-133a (miR-133a) has inhibitory effects on cell proliferation, migration, invasion, and metastasis of osteosarcoma. Methods: MiR-133a expression in human osteosarcoma cell lines and human normal osteoblastic cell line hFOB was investigated by real-time PCR (RT-PCR). The role of miR-133a in human osteosarcoma growth and invasion was assessed in cell lines in vitro and in vivo. Then, luciferase reporter assay validated IGF-1R as a downstream and functional target of miR133a, and functional studies revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of IGF-1R expression. Results: MiR-133a was lower expressed in human osteosarcoma cell lines than human normal osteoblastic cell line hFOB and its effect on inhibiting proliferation, invasion and metastasis is mediated by its direct interaction with the IGF-1R. Furthermore, the tumour-suppressive function of miR-133a probably contributed to inhibiting the activation AKT and ERK signaling pathway. Conclusion: MiR-133a suppresses osteosarcoma progression and metastasis by targeting IGF-1R in human osteosarcoma cells, providing a novel candidate prognostic factor and a potential anti-metastasis therapeutic target in osteosarcoma.
MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion via Targeting IGF-1R

Introduction
Osteosarcoma (OS) is the most common primary bone sarcoma, occurring predominantly in children and adolescents, and is associated with high rates of metastasis and recurrence [1] . Although the development of multi-agent chemotherapies and surgical techniques that improve surgical margins [2] and allow reconstruction [3] have significantly improved the survival of patients with osteosarcoma, the prognosis remains poor, owing to high invasiveness and metastasis potential of the disease. The molecular mechanisms involved in osteosarcoma progression and metastasis have not yet been elucidated. Work along such lines is essential for the development of novel prognostic biomarkers and targeted gene therapies for this malignancy.
MicroRNAs (miRNAs) are small molecules 17-22 nucleotides in length that play important roles in a variety of biological processes, including development and cellular differentiation, apoptosis, proliferation, and senescence [4] [5] [6] . miRNAs affect transcriptional and post-transcriptional regulation of gene expression by binding to the 3′-untranslated regions (3′-UTRs) of target mRNAs, thereby suppressing protein translation [7] . Previous studies found that miRNAs are involved in many normal biological processes; aberrant miRNA expression has been associated with both oncogenesis and tumor suppression [5, 8, 9] .
Among many miRNAs known to be involved in cancer, miR-133a is abnormally expressed in various forms of carcinomas, including lung cancer, breast cancer, hepatocellular carcinoma, and osteosarcoma [10] [11] [12] [13] . Several studies has demonstrated many miRNAs expression signature associated with tumorigenesis, tumor growth, and metastasis in osteosarcoma [14] [15] [16] . In the present study, we found that miR-133a was expressed at lower levels in human osteosarcoma cell lines but at a high level in normal human osteoblastic cells. miR133a inhibited the osteosarcoma invasive-metastatic cascade in several ways, notably by suppressing cell proliferation, migration, and invasion. In addition, we used bioinformatics, real-time PCR (RT-PCR), Western blotting, and luciferase reporter assays to show that miR133a targeted IGF-1R in osteosarcoma cells. Furthermore, we also identified the specific role and underlying molecular mechanism of miR-133a involvement in osteosarcoma cell proliferation and invasion.
Materials and Methods
Cell lines and cell cultures
The human normal osteoblastic cell line hFOB and the human osteosarcoma cell lines Saos, HOS, and U2OS were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China) and maintained at 37°C under 5% (v/v) CO 2 in DMEM and RPMI 1640 medium, respectively. The media were supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin.
RNA extraction and RT-PCR
Total RNA, including miRNA, was extracted using Trizol Reagent (Invitrogen, USA) according to the manufacturer's instructions. The RNA quality and integrity were evaluated by calculation of A260/ A280 ratios. miRNA was converted to cDNA using the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, USA), and RT-PCR was performed employing a LightCycler (Roche) and SYBR RT-PCR kit (Takara). The PCR primers for miR133a were 5′-TTT GGT CCC CTT CAA CC-3′ (forward) and 5′-GTG CAG GGT CCG AGG T-3′ (reverse) (forward) and 5′-GTT TAA GCA CTT CGC AAG GTA TA-3′ (reverse); those for small nuclear RNA (U6) were 5′-CAA ATT CGT GAA GCG TTC CAT AT-3′(forward) and 5′-GTG CAG GGT CCG AGG T-3′ (reverse) [17] . One microgram of total RNA was used for first-strand cDNA synthesis using the PrimeScript™ RT reagent kit (Takara Biomedical, Shiga, Japan). RT-PCR was performed in triplicate reactions using SYBR Premix Ex Taq (Takara). The specific primers were as follows: 5′ CCG CTG CCA GAA AAT GTG CCC A-3′ (forward) and 5′-TGT CGT TGT CAG GCG CGC TG-3′ (reverse) for IGF-1R, and 5′-TGA CTT CAA CAG CGA CAC CCA-3′ (forward) and 5-CAC CCT GTT GCT GTA GCC AAA -3′ (reverse) for GAPDH. U6 and GAPDH served as internal controls for the miRNA and mRNA assays, respectively. The threshold cycle (Ct) values were determined using the 2−ΔΔCt cycle threshold method.
Cell transfection
A miR-133a mimic (miR) was used to restore miR-133a expression; the negative control miRNA was miR-NC (Thermo Fisher Scientific, Cleveland, OH, USA). hU6-MCS-CMV-EGFP was used as the vector for ectopic overexpression of miR-133a (miR-133a-o), and empty hU6-MCS-CMV-EGFP served as the negative control (miR-133a-o-NC). Both agents were constructed by GeneChem (Shanghai, China). U2OS and Saos cells were infected with these lentiviral constructs using Lipofectamine 2000 (Invitrogen). A siRNA targeting human IGF-1R (si-IGF-1R) and a negative control (si-IGF-1R-NC) were designed and synthesized by GeneChem. All constructs and oligonucleotides were transfected into U2OS and Saos cells using Lipofectamine 2000, according to the manufacturer's instructions; the final concentrations were 100 nM. Transfection efficiencies were evaluated by performing RT-PCR 48 h post-transfection.
Western blotting
Western blotting was performed in a routine manner. Briefly, cell protein extracts were subjected to SDS-PAGE and transferred to PVDF membranes. After washing and blocking in Tris-buffered saline/Tween 20 containing 5% (w/v) nonfat dry milk, the blocked membranes were incubated with primary antibodies followed by HRP-conjugated secondary antibodies. Membranes were developed using the enhanced chemiluminescence method (Pierce, Rockford, IL, USA). The antibodies used were anti-IGF-1R (1:500, Santa Cruz, CA, USA) and anti-phospho-AKT (p-AKT) (1:1,000), anti-AKT (1:1,000), anti-phospho-extracellular signal-regulated kinase (p-ERK) (1:1,000), anti-ERK (1:1,000), and anti-GAPDH (1:2,000) (all from Cell Signaling Technology, USA).
Cell proliferation assay
Cells were plated at 2,000/well in triplicate wells of 96-well culture plates and incubated for 0, 24, 48, or 72 h at 37°C under 5% (v/v) CO 2 . At the indicated time points, 10 μL CCK-8 solution (Dojindo, Japan) were added to each well, and after incubation for another 2 h, the OD value at 450 nm was measured on an Infinite 200 spectrometer. Each assay was performed in triplicate and repeated three times.
Migration and invasion assays
Cell migration assays were performed using 24-well transwell plates containing 8.0-μm-pore-diameter polycarbonate membrane inserts (Corning, NY, USA). A total of 1×10 5 cells were suspended in 100 μL highglucose DMEM or RPMI 1640 medium (Gibco BRL, USA) with 1% (v/v) FBS (Gibco) and added to the upper chamber. The lower chamber was filled with 600 μL high-glucose DMEM or RPMI 1640 medium (Gibco BRL, USA) with 10% (v/v) FBS (Gibco). After incubation for 24 h, cells on the upper surface of the membrane were removed, and cells that had migrated to the lower surface were fixed in 4% (v/v) paraformaldehyde and stained with 0.1% (w/v) crystal violet for 15 min at room temperature. Ten fields were counted under a 100× objective. Mean ± standard deviation (SD) cell numbers were then calculated. The cell invasion assay was performed in a similar manner, except that the cells were seeded onto Matrigel-coated filters (BD Biosciences, Franklin Lakes, NJ, USA).
In vivo assays of tumor growth and metastasis
All animal experiments were performed in accordance with current guidelines and followed a protocol approved by the Animal Care and Use Committee of Zhejiang University, China. Athymic nude BALB/c mice (4 weeks of age, Shanghai Laboratory Animal Center, Chinese Academy of Science, Shanghai, China) were raised under specific pathogen-free conditions. The mice were inoculated subcutaneously with 1×10 Single-cell suspensions of Saos-miR-133a-o or Saos-miR-133a-o-NC cells in 0.1 mL PBS were injected into the lateral tail vein of 4-week-old BALB/c nude mice. Subsequent deaths were recorded; the remaining mice were sacrificed at 8 weeks and lung metastasis evaluated (n=5 per group). Lungs were removed and fixed in 10% (v/v) formalin, and the numbers of lung nodules were counted under a dissecting microscope. Serial tissue sections of the excised tumors were stained with hematoxylin and eosin and examined microscopically.
Luciferase reporter assays
Wildtype and mutant 3′-UTRs of IGF-1R were amplified and cloned downstream of the luciferase gene within the pGL3/luciferase vector (Promega, Madison, WI, USA). Luciferase activities of the transformed cells were measured using the Dual-Luciferase Reporter Assay System (Promega) 48 h after transfection, according to the manufacturer's protocol. The Renilla luciferase plasmid (pRL-TK, Promega) was cotransfected as a control.
Statistical analysis
All data are shown as means ± SD; all experiments were repeated independently at least three times. Between-group comparisons were performed using Student's t-test, Pearson's χ2 test, or Fisher's exact test. The associations between the miR-133a expression level and clinical and pathological variables were analyzed using Pearson's χ2 test. All statistical analyses were performed using SPSS version 19.0 for Windows. A two-sided p value < 0.05 was considered to reflect statistical significance.
Results
miR-133a is downregulated in osteosarcoma cell lines
To explore the role played by miR-133a in osteosarcoma development, we first examined miR-133a expression by real-time PCR in the normal human osteoblastic cell line hFOB and the human osteosarcoma cell lines U2OS, HOS, and Saos. miR-133a expression was significantly decreased in the osteosarcoma cell lines ( Fig. 1 ; **p < 0.01). This suggested that miR-133a is downregulated in osteosarcoma cells and thus might play a role in inhibiting human osteosarcoma development.
miR-133a suppresses the proliferation of osteosarcoma cells
To explore the effect of miR-133a on osteosarcoma cell proliferation, miR-133a was overexpressed using a miR-133a mimic in U2OS and Saos cells, which express low levels of endogenous miR-133a. miR-133a overexpression in transfected U2OS and Saos cell lines was confirmed by RT-PCR ( Fig. 2a and b ; **p < 0.01).
Next, cell proliferation rates were measured using the CCK-8 assay. Overexpression of miR-133a significantly increased the proliferation of U2OS and Saos cells ( Fig. 2c and d ; *p < 0.05). Fig. 1 . miR-133a is downregulated in osteosarcoma cell lines. Real-time PCR was used to quantify the endogenous levels of miR-133a in the normal human osteoblastic cell line hFOB and the human osteosarcoma cell lines U2OS, HOS, and Saos. U6 served as the control for RNA loading; the expression levels of miR-133a were normalized to those of U6 RNA.
miR-133a inhibits the migration and invasion of osteosarcoma cells in vitro
Migration and invasion of osteosarcoma cells were measured in vitro by loss-and gainof-function transwell assays. Overexpression expression of miR-133a remarkably suppressed migration and invasion, compared with wild-type and control-transfected U2OS and Saos cells ( Fig. 3a and b ; **p < 0.01). Together, the results suggested that miR-133a significantly inhibited the invasion and migration of osteosarcoma cells. 
miR-133a suppresses osteosarcoma growth and metastasis in vivo
To investigate the effects of miR-133a on tumor growth in vivo, miR-133a was stably overexpressed via lentiviral vectors in Saos cells, which express low levels of endogenous miR-133a. Stable overexpression of miR-133a in the transfected line was confirmed by RT-PCR ( Fig. 4a ; **p < 0.01). We next injected Saos cells subcutaneously into nude mice. Compared with the Saos-miR-NC group, miR-133a overexpression in Saos cells significantly decreased tumor size (Figs. 4b and c; **P<0.01).
To explore whether self-seeding by circulating tumor cells (CTCs) is relevant in osteosarcoma development, we established a model of metastatic osteosarcoma. We injected Saos tumor cells into the lateral tail veins of nude mice and sought evidence of CTC seeding. The Saos-miR-NC group developed lung and liver metastases, whereas the Saos-miR-133a group had fewer metastases in both tissues. The numbers of lung and liver metastatic nodules revealed by hematoxylin-and-eosin staining were significantly higher in the SaosmiR-NC than the Saos-miR-133a group (Figs. 4d and e; **p < 0.01).
IGF-1R is a downstream target of miR-133a
To further investigate the molecular basis of miR-133a function in osteosarcoma cells, we identified the molecular targets of miR-133a. The TargetScan database (http://www. targetscan.org) predicted binding sites for miR-133a within IGF-1R. As shown in Figure 5a , miR-133a was predicted to bind to one site within the 3′-UTR of IGF-1R mRNA. Our results showed that luciferase activity was suppressed in U2OS-miR-133a and Saos-miR-133a cells (Figs. 5b and c; **p < 0.01), whereas the miR-133a-mutant plasmids did not affect reporter gene activity, suggesting that IGF-1R might be a target of miR-133a. Furthermore, we detected IGF-1R mRNA and protein expression levels in U2OS-miR-133a and Saos-miR-133a cells, and the corresponding control cells to determine whether miR-133a overexpression reduced the expression of endogenous IGF-1R. Consistent with the Dual Luciferase reporter data, we found that IGF-1R mRNA and protein levels were decreased in U2OS-miR-133a and Saos-miR-133a cells (Figs. 5d and e; *p < 0.05). These results indicate that miR-133a binds directly to the 3′-UTR of IGF-1R, consequently inhibiting IGF-1R expression.
IGF-1R induces proliferation of, and invasion by, osteosarcoma cells
To investigate the roles played by IGF-1R in the miR-133a-inhibited proliferation and invasion of osteosarcoma cells, we explored whether knockdown of endogenous IGF-1R mimicked the effect of miR-133a restoration. Transfection of si-IGF-1R significantly suppressed IGF-1R expression in U2OS and Saos cells (which express low levels of miR-133a and high levels of IGF-1R) (Figs. 6a and b; **p < 0.01). Transfection of si-IGF-1R significantly inhibited the proliferation and invasion of osteosarcoma cells (Figs. 6c-f ; **p < 0.01), suggesting that the tumor suppressor functions of miR-133a may be exerted via inhibition of IGF-1R.
miR-133a targets IGF-1R in osteosarcoma cells by activating the ERK/AKT signaling pathway
IGF-1R has a crucial role in the growth, cell cycle, and apoptosis of human tumors by activating several downstream signaling cascades, including the AKT and the ERK signaling pathways [18] [19] [20] . Therefore, we hypothesized that by targeting IGF-1R, miR-133a might affect the ERK/AKT signaling pathway in osteosarcoma cells.
Western blotting was used to measure AKT, pAKT, ERK, and p-ERK protein levels in Saos cells after transfection with the miR-133a mimic or si-IGF-1R. The levels of p-AKT, p-ERK, and IGF-1R decreased in Saos-miR-NC cells compared with Saos-miR-133a cells, but the total AKT and ERK levels did not significantly change, after transfection with a miR-133a mimic (Fig. 7a) . Similarly, the levels of p-AKT, p-ERK, and IGF-1R were lower in Saos-si- IGF-1R cells compared with Saos-si-IGF-1R-NS cells, whereas the total AKT and ERK levels did not significantly change, after si-IGF-1R treatment (Fig. 7b) . These results indicate that miR-133a serves as a tumor suppressor in osteosarcoma cells by targeting IGF-1R and thus indirectly regulating the ERK and AKT signaling pathways. 
Discussion
The present study showed that miR-133a plays a critical role in inhibiting the growth and metastasis of osteosarcoma cells. miR-133a targets IGF-1R and represses its expression. miR-133a overexpression thus indirectly inhibits activation of the ERK and AKT signaling pathways, which probably contributes to suppression of osteosarcoma cell growth and metastasis. First, we confirmed that miR-133a levels were low in osteosarcoma cells compared with the normal human osteoblastic cell line hFOB. We next showed that miR133a overexpression suppressed growth and invasion of osteosarcoma cells, both in vitro and in vivo. Furthermore, we described a novel functional link between miR-133a and IGF-1R in the context of osteosarcoma development. Our results revealed that miR-133a plays a substantial role in tumor inhibition and may serve as a therapeutic target in osteosarcoma patients.
A growing body of evidence suggests that miRNAs are valuable molecular biomarkers in terms of cancer diagnosis, prognosis, and therapy; miRNAs regulate many oncobiological processes such as tumorigenesis, tumor growth, and metastasis [5, 8] . Thus, miRNAs may potentially serve as molecular targets in cancer therapy. Several studies has demonstrated many miRNAs expression signature associated with cell proliferation, migration, and invasion in osteosarcoma [14] [15] [16] . Of the various miRNAs, miR-133a has been shown to exert tumor suppressor functions in many types of human cancers, including non-small cell lung cancer [21] , gastric cancer [22] , colorectal cancer [23] , esophageal squamous cell carcinoma [24] , ovarian cancer [25] , and osteosarcoma [26] . Fujiwara et al. [27] found that down-regulation of miR-133a was inversely associated with the overall survival of osteosarcoma patients, suggesting that miR-133a potentially inhibits osteosarcoma development. Similarly, Fang et al. [26] found that down-regulation of miR-133a suppressed osteosarcoma tumor growth and promoted apoptosis, indicating that miR-133a might be involved in carcinogenesis. However, the molecular mechanism by which miR-133a regulates osteosarcoma cell proliferation and invasion remains largely unknown. Here, we provide compelling biological evidence that miR-133a expression is markedly downregulated in osteosarcoma cells, and that miR-133a acts to promote the proliferation and invasion of such cells, further supporting the notion that miR-133a inhibits tumor development.
IGF-1R is a member of the insulin receptor family of receptor tyrosine kinases [28] , which regulate cell proliferation, apoptosis, motility, and transformation [29] . Considerable evidence indicates that IGF-1R is overexpressed in various cancers, including osteosarcoma [30] [31] [32] [33] . IGF-1R has previously been reported to be a target of miR-133a in lung cancer [30] , gastric cancer [34] and hepatocellular carcinoma [33] . However, no interaction between miR133a and IGF-1R in osteosarcoma cells has been shown previously. In addition, abnormal IGF-1R expression was found to affect several downstream pathways, including the AKT and ERK signaling pathways, which are involved in tumorigenesis and tumor development [18] [19] [20] . Herein, we provide evidence that miR-133a negatively regulates the proliferation and invasion of osteosarcoma cells. miR-133a targets IGF-1R and thus indirectly inhibits activation of the AKT/ERK signaling pathways.
In conclusion, our results show, for the first time, that miR-133a exerts tumor suppressor functions; miR-133a targets IGF-1R in osteosarcoma cells and thus, indirectly, the AKT/ERK signaling pathways. The pleiotropic roles played by miR-133a in terms of osteosarcoma growth and metastasis indicate that miR-133a serves as a therapeutic agent for osteosarcoma patients. Further study is required.
